Description

Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury[1].[2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-programmed cell death–C37H49N7O9S—-[1]Smith AJ, et al. Characterisation of CCKB receptors on GH3 pituitary cells: receptor activation is linked to Ca2+ mobilisation. Eur J Pharmacol. 1994 Apr 15;267(2):215-23.|[2]Tanaka S, et al. Pentagastrin gastroprotection against acid is related to H2 receptor activation but not acid secretion. Gut. 1998 Sep;43(3):334-41.–5534-95-2–767.89–99.97–O=C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@H](C(N)=O)CC1=CC=CC=C1)=O)=O)[C@@H](NC(CCNC(OC(C)(C)C)=O)=O)CC2=CNC3=C2C=CC=C3–Cancer; Endocrinology–DMSO : ≥ 34 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)–Cholecystokinin Receptor–CCKBR–GPCR/G Protein;Neuronal Signaling–Peptides